Back to Search
ALEXANDER COLEVAS, MD
MD
Medical Oncology Physician
NPI: 1588726558IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D0041607(MD)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
C52711(CA)
Education
HARVEY MEDICAL COLLEGE
Research & Publications (20)
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
PMID 16763278·J Clin Oncol·2006
6-review
Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
PMID 15700626·Oncology (Williston Park)·2004
7-preclinical
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
PMID 11943893·Am J Clin Oncol·2002
3-trial
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck.
PMID 11466686·Cancer·2001
3-trial
Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck.
PMID 11597798·Int J Radiat Oncol Biol Phys·2001
3-trial
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
PMID 10907945·Ann Oncol·2000
3-trial
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer.
PMID 19117692·Int J Radiat Oncol Biol Phys·2009
8-other
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
PMID 18691173·Br J Haematol·2008
3-trial
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
PMID 18038218·Invest New Drugs·2008
3-trial
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
PMID 17505006·Clin Cancer Res·2007
7-preclinical
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
PMID 17003373·Blood·2007
3-trial
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
PMID 17084620·Eur J Cancer·2007
3-trial
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
PMID 17364235·Invest New Drugs·2007
3-trial
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
PMID 17457044·Cancer Biol Ther·2007
3-trial
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
PMID 17470857·J Clin Oncol·2007
3-trial
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
PMID 17671131·Clin Cancer Res·2007
3-trial
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
PMID 17960013·N Engl J Med·2007
3-trial
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
PMID 17991931·J Clin Oncol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 PASTEUR DR
PALO ALTO, CA 94304 - Phone
- (650) 723-4000
Quick Facts
- NPI
- 1588726558
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile